Resflor

Manufacturer
Merck Sharp & Dohme Corp.
Effective date
2026-09-10
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
6
Source
daily-update
Hydrated at
2026-09-19 01:00:34

Label at a glance#

ProductResflor Gold
Active ingredientFLORFENICOL, FLUNIXIN MEGLUMINE
Label structure18 sections

Storage and handling

STORAGE INFORMATION: Do not store above 30°C (86°F). Use within 28 days of first use.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

(Florfenicol and Flunixin Meglumine)
Antimicrobial/Non-Steroidal Anti-Inflammatory Drug

For subcutaneous use in beef and non-lactating dairy cattle only.

Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

PRODUCT INFORMATION

SPL UNCLASSIFIED SECTION

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION SECTION

DESCRIPTION: RESFLOR GOLD® is an injectable solution of the synthetic antibiotic florfenicol and the non-steroidal anti-inflammatory drug (NSAID) flunixin. Each milliliter of sterile RESFLOR GOLD® contains 300 mg florfenicol, 16.5 mg flunixin as flunixin meglumine, 300 mg 2-pyrrolidone, 35 mg malic acid, and triacetin qs.

INDICATIONS & USAGE SECTION

INDICATION: RESFLOR GOLD® is indicated for treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and control of BRD-associated pyrexia in beef and non-lactating dairy cattle.

DOSAGE & ADMINISTRATION SECTION

DOSAGE AND ADMINISTRATION: RESFLOR GOLD® should be administered once by subcutaneous injection at a dose rate of 40 mg florfenicol/kg body weight and 2.2 mg flunixin/kg body weight (6 mL/100 lb). Do not administer more than 10 mL at each site. The injection should be given only in the neck. Injection sites other than the neck have not been evaluated. For the 500 mL vial, do not puncture the stopper more than 20 times.

RESFLOR GOLD® Dosage Guide*
ANIMAL WEIGHT
(lbs)
DOSAGE
(mL)
1006.0Recommended Injection Location
FigureFigure
20012.0
30018.0
40024.0
50030.0
60036.0
70042.0
80048.0
90054.0
100060.0

* Do not administer more than 10 mL at each site.

CONTRAINDICATIONS SECTION

CONTRAINDICATIONS: Do not use in animals that have shown hypersensitivity to florfenicol or flunixin.

WARNINGS SECTION

WARNINGS: NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. This product contains material that can be irritating to skin and eyes. Avoid direct contact with skin, eyes, and clothing. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Consult a physician if irritation persists. Accidental injection of this product may cause local irritation. Consult a physician immediately. The Safety Data Sheet (SDS) contains more detailed occupational safety information.

For customer service, adverse effects reporting, and/or a copy of the SDS, call 1-800-211-3573. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDAVETS, or www.fda.gov/reportanimalae.

PRECAUTIONS SECTION

PRECAUTIONS: As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal, and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for adverse events are those that are dehydrated, on diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully monitored. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that have not been previously diagnosed. Since many NSAIDs possess the potential to produce gastrointestinal ulceration, concomitant use of RESFLOR GOLD® with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided or closely monitored.

Flunixin is a cyclo-oxygenase inhibitory NSAID, and as with others in this class, adverse effects may occur with its use. The most frequently reported adverse effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported for other drugs in this class.

Not for use in animals intended for breeding purposes. The effects of RESFLOR GOLD® on bovine reproductive performance, pregnancy, and lactation have not been determined. Toxicity studies in dogs, rats, and mice have associated the use of florfenicol with testicular degeneration and atrophy. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. Studies have associated the use of flunixin in cattle with a delay in parturition and prolonged labor (which may increase the risk of stillbirth), and interference with involution and expulsion of fetal membranes (which may increase the risk for placental retention and metritis).

RESFLOR GOLD®, when administered as directed, may induce a transient reaction at the site of injection and underlying tissues that may result in trim loss of edible tissue at slaughter.

RESIDUE WARNING SECTION

RESIDUE WARNINGS: Animals intended for human consumption must not be slaughtered within 38 days of treatment. This product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal.

ADVERSE REACTIONS SECTION

ADVERSE REACTIONS: Transient inappetence, diarrhea, decreased water consumption, and injection site swelling have been associated with the use of florfenicol in cattle. In addition, anaphylaxis and collapse have been reported post-approval with the use of another formulation of florfenicol in cattle.

In cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use of flunixin meglumine.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

The pharmacokinetics (PK) of florfenicol (Table 1) and flunixin (Table 2) after subcutaneous injection of RESFLOR GOLD® is described below:

Table 1. Mean (n=28) pharmacokinetic parameters for florfenicol in cattle after a single subcutaneous administration of RESFLOR GOLD (florfenicol dose of 40 mg/kg BW).
Mean Florfenicol PK parameters in Cattle
PK
Parameter
AUC0-t
(ng*hr/mL)
AUC0-inf
(ng*hr/mL)
Cmax
(ng/mL)
Tmax (hr)T½ (hr)MRT0-inf (hr)
Mean242527247577111516.2528.527.3
SD 427414139141943.879.9111.6
Table 2. Mean (n=28) pharmacokinetic parameters for flunixin in cattle after a single subcutaneous administration of RESFLOR GOLD (flunixin dose of 2.2 mg/kg BW).
Mean Flunixin PK parameters in Cattle
PK
Parameter
AUC0-t *
(ng*hr/mL)
AUC0-inf †
(ng*hr/mL)
Cmax ‡
(ng/mL)
Tmax § (hr)T½ (hr)MRT0-inf # (hr)
Mean1337014448♠ 19131.149.5♠ 11.4
SD♥ 496451167910.973.274.41

* AUC0-t = Area under the plasma-concentration-time curve (AUC) from time zero to the last quantifiable concentrations

† AUC0-inf = AUC from time zero to infinity

‡ Cmax = Maximum plasma concentration

§ Tmax = Time at which Cmax was observed

T½ = Terminal elimination half-life

# MRT0-inf = Mean residence time from time zero to infinity

♠ n=27

♥ SD = Standard deviation

MICROBIOLOGY SECTION

MICROBIOLOGY: Florfenicol is a synthetic, broad-spectrum antibiotic active against many Gram-negative and Gram-positive bacteria isolated from domestic animals. It acts by binding to the 50S ribosomal subunit and inhibiting bacterial protein synthesis. Florfenicol is generally considered a bacteriostatic drug, but exhibits bactericidal activity against certain bacterial species.

In vitro studies demonstrate that florfenicol is active against the BRD pathogens M. haemolytica, P. multocida, and H. somni, and M. bovis that florfenicol exhibits bactericidal activity against strains of M. haemolytica and H. somni.

The minimum inhibitory concentrations (MICs) of florfenicol were determined for non-mycoplasmal BRD isolates obtained from calves enrolled in BRD field studies in the U.S. in 2006 using methods recommended by the Clinical and Laboratory Standards Institute (M31-A2). MICs for M. bovis isolates were determined by an accepted method using Hayflick Broth with Alamar Blue (HBAN) medium under appropriate control. Isolates were obtained from pre-treatment nasal swabs from all calves enrolled at all four sites, post-treatment nasal swabs from treatment failures in the RESFLOR GOLD and saline control treatment groups at three sites, and lung tissue from one calf that died in the saline control treatment group. The results are shown in belowTable 3.

Table 3. Florfenicol MIC values* of indicated pathogens isolated from cattle with naturally-ocurring BRD.
Indicated pathogensYear of isolationNumber of isolatesMIC50 †
(μg/mL)
MIC90 †
(μg/mL)
MIC range
(μg/mL)
Mannheimia haemolytica20061831.01.00.5 to 32
Pasteurella multocida20061390.50.5≤ 0.125 to 16
Histophilus somni200684≤ 0.125≤ 0.125≤ 0.125 to 0.25
Mycoplasma bovis2006601.01.00.5 to 1.0

* The correlation between in vitro susceptibility data and clinical effectiveness is unknown.

† The lowest MIC to encompass 50% and 90% of the most susceptible isolates, respectively.

SPL UNCLASSIFIED SECTION

EFFECTIVENESS: In a multi-site field study, calves with naturally-occurring BRD were treated with RESFLOR GOLD®, Nuflor Gold® (NADA 141-265), or saline. A treatment success was defined as a calf with normal respiration to mild respiratory distress, normal attitude to mildly depressed, and a rectal temperature < 104.0 °F on Day 11.

The treatment success rate for BRD for the RESFLOR GOLD® treatment group (68.4%) was statistically significantly greater (p = 0.0255) compared to the saline control treatment group (42.9%). RESFLOR GOLD® was non-inferior to Nuflor Gold® for the treatment of BRD, with a one-sided 95% lower confidence bound for the difference between the two treatments equal to -13.2%.

In the same study, the change in rectal temperature from pre-treatment to six hours post-treatment was evaluated to determine the effectiveness of RESFLOR GOLD® for the control of BRD-associated pyrexia. The proportion of calves whose rectal temperatures decreased by ≥ 2.0 °F from pre-treatment to six hours post-treatment was statistically significantly greater (p = 0.0019) in the RESFLOR GOLD® treatment group compared to the saline control treatment group. The mean decrease in rectal temperature from pre-treatment to six hours post-treatment was statistically significantly greater in the RESFLOR GOLD® treatment group compared to the Nuflor Gold® and saline control treatment groups (p = 0.0031 and 0.0002, respectively).

The effectiveness of RESFLOR GOLD for the treatment of BRD associated with Mycoplasma bovis was demonstrated by examining the M. bovis data from cattle enrolled in the BRD treatment study described above. There were numerically more treatment successes (6 of 8 calves, 75%) than treatment failures (2 of 8 calves, 25%) in RESFLOR GOLD-treated calves that cultured positive for M. bovis pre-treatment.

FOOD SAFETY WARNING SECTION

ANIMAL SAFETY: A target animal safety study was conducted to evaluate the effects of RESFLOR GOLD® when administered to cattle subcutaneously at 1X, 3X, or 5X the labeled dose for three consecutive days (3X the labeled duration). Decreased feed and water consumption, and decreased body weights (secondary to decreased feed consumption) were observed in the 1X, 3X, and 5X groups. Injection site swellings were noted in the 1X, 3X, and 5X groups.

A separate injection site study was conducted in cattle. The study demonstrated that RESFLOR GOLD®, when administered according to the label directions, may induce a transient local reaction in the subcutaneous and underlying muscle tissue.

STORAGE AND HANDLING SECTION

STORAGE INFORMATION: Do not store above 30°C (86°F). Use within 28 days of first use.

HOW SUPPLIED SECTION

HOW SUPPLIED: RESFLOR GOLD® is available in 100, 250, and 500 mL sterile, multiple-dose, glass vials.

SPL UNCLASSIFIED SECTION

Made in Germany
Intervet Inc. (d/b/a Merck Animal Health)
126 E. Lincoln Ave., Rahway, NJ, 07065
Copyright © 2026 Merck & Co., Inc.,
Rahway, NJ, USA and its affiliates. All rights reserved
Rev. 07/26

Approved by FDA under NADA # 141-299
255167 R1

PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

100 mL
Multiple Dose Vial
300mg/16.5mg/mL

Sterile

Resflor
GOLD®
Florfenicol and
Flunixin Meglumine

(Florfenicol and Flunixin Meglumine)
Antimicrobial/Non-Steroidal Anti-Inflammatory Drug

For subcutaneous use in beef and
non-lactating dairy cattle only.
Not for use in female dairy cattle
20 months of age or older or in calves
to be processed for veal.

CAUTION: Federal law restricts
this drug to use by or on the order of
a licensed veterinarian.

Approved by FDA under
NADA # 141-299

MERCK
Animal Health

PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton
PRINCIPAL DISPLAY PANEL - 100 mL Vial Carton

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
FlorfenicolACTIVE INGREDIENT9J97307Y1H3
Flunixin MeglumineACTIVE INGREDIENT8Y3JK0JW3U3
FlorfenicolACTIVE MOIETY9J97307Y1H3
FlunixinACTIVE MOIETY356IB1O4003
malic acidINACTIVE INGREDIENT817L1N4CKP3
PYRROLIDONEINACTIVE INGREDIENTKKL5D39EOL3
triacetinINACTIVE INGREDIENTXHX3C3X6733

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0061-43050061-4305-01, 0061-4305-02, 0061-4305-03

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
FLORFENICOL9J97307Y1HACTIB
FLUNIXIN MEGLUMINE8Y3JK0JW3UACTIB

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
52024-11-19full-release2026-06-01 02:43:54

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 19 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
triacetinTRIACETINXHX3C3X673TABLET, DELAYED RELEASE / ORAL23 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673CAPSULE, DELAYED RELEASE / ORAL5.1 mgExact identifier — unii candidate
14 equally ranked IID candidates
malic acidMALIC ACID817L1N4CKPSUSPENSION / ORAL180 mgExact identifier — unii candidate
5 equally ranked IID candidates
malic acidMALIC ACID817L1N4CKPSOLUTION / ORAL16760 mgExact identifier — unii candidate
5 equally ranked IID candidates
malic acidMALIC ACID817L1N4CKPTABLET / ORAL20 mgExact identifier — unii candidate
5 equally ranked IID candidates
malic acidMALIC ACID817L1N4CKPPOWDER, FOR SOLUTION / ORAL1230 mgExact identifier — unii candidate
5 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673CONCENTRATE / ORAL250 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673CAPSULE, EXTENDED RELEASE / ORAL467 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673TABLET, EXTENDED RELEASE / ORAL26 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673CAPSULE / ORAL13 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673POWDER, FOR SUSPENSION / ORAL12 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673SUSPENSION, EXTENDED RELEASE / ORAL4 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673TABLET, FILM COATED / ORAL15.12 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673SYSTEM / TRANSDERMAL22.1 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673TABLET, COATED / ORAL1 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673SUSPENSION / ORAL7 mgExact identifier — unii candidate
14 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673TABLET / ORAL208 mgExact identifier — unii candidate
14 equally ranked IID candidates
malic acidMALIC ACID817L1N4CKPPOWDER, FOR SUSPENSION / ORAL1392 mgExact identifier — unii candidate
5 equally ranked IID candidates
triacetinTRIACETINXHX3C3X673TABLET, CHEWABLE, EXTENDED RELEASE / ORAL2 mgExact identifier — unii candidate
14 equally ranked IID candidates

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.